BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet 2019;58:859-74. [PMID: 30758736 DOI: 10.1007/s40262-019-00742-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Barnett C, Tabasinejad R, Bril V. Current pharmacotherapeutic options for myasthenia gravis. Expert Opin Pharmacother 2019;20:2295-303. [PMID: 31670984 DOI: 10.1080/14656566.2019.1682548] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
2 Cheng WY, Sarda SP, Mody-patel N, Krishnan S, Yenikomshian M, Kunzweiler C, Vu JD, Cheung HC, Duh MS. Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population. CEOR 2022;Volume 14:357-69. [DOI: 10.2147/ceor.s346816] [Reference Citation Analysis]
3 Mihalcik L, Chow V, Ramchandani M, Hinkle B, McBride HJ, Lebrec H. Use of nonclinical toxicity studies to support biosimilar antibody development. Regul Toxicol Pharmacol 2021;122:104912. [PMID: 33662478 DOI: 10.1016/j.yrtph.2021.104912] [Reference Citation Analysis]
4 Chow V, Pan J, Chien D, Mytych DT, Hanes V. A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris® ) in healthy male subjects. Eur J Haematol 2020;105:66-74. [PMID: 32196749 DOI: 10.1111/ejh.13411] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
5 Wijnsma KL, Ter Heine R, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ. Author's Reply to Liu et al.: "Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab". Clin Pharmacokinet 2020;59:1645-6. [PMID: 33118148 DOI: 10.1007/s40262-020-00952-5] [Reference Citation Analysis]
6 Menon D, Urra Pincheira A, Bril V. Emerging drugs for the treatment of myasthenia gravis. Expert Opin Emerg Drugs 2021;26:259-70. [PMID: 34228579 DOI: 10.1080/14728214.2021.1952982] [Reference Citation Analysis]
7 Iorember F, Nayak A. Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring. Pediatr Nephrol 2021;36:1365-75. [PMID: 32529325 DOI: 10.1007/s00467-020-04652-x] [Reference Citation Analysis]
8 Peffault de Latour R, Brodsky RA, Ortiz S, Risitano AM, Jang JH, Hillmen P, Kulagin AD, Kulasekararaj AG, Rottinghaus ST, Aguzzi R, Gao X, Wells RA, Szer J. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. Br J Haematol 2020;191:476-85. [PMID: 32449174 DOI: 10.1111/bjh.16711] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
9 Weber B, Chan D, Hammer S. Eculizumab Use in a Temporarily Dialysis-Dependent Patient With Shiga Toxin-Producing Escherichia Coli Hemolytic Uremic Syndrome With Neurological Complications. J Pediatr Pharmacol Ther 2022;27:90-5. [PMID: 35002565 DOI: 10.5863/1551-6776-27.1.90] [Reference Citation Analysis]
10 Mahroum N, Zoubi M, Lavine N, Ohayon A, Amital H, Shoenfeld Y. The mosaic of autoimmunity - A taste for more. The 12th international congress of autoimmunity 2021 (AUTO12) virtual. Autoimmun Rev 2021;20:102945. [PMID: 34509655 DOI: 10.1016/j.autrev.2021.102945] [Reference Citation Analysis]
11 Horváth O, Kelen K, Prohászka Z, Hosszú Á, Szabó AJ, Reusz GS. Atypical HUS and Crohn's disease-interference of intestinal disease activity with complement-blocking treatment. Pediatr Nephrol 2021. [PMID: 34328541 DOI: 10.1007/s00467-021-05167-9] [Reference Citation Analysis]
12 Liu J, Memon AA, Lyu L, Siedlecki A. Comment on "Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab". Clin Pharmacokinet 2020;59:1641-3. [PMID: 33118149 DOI: 10.1007/s40262-020-00950-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Vitkauskaitė M, Vinikovas A, Miglinas M, Rimševičius L, Čerkauskaitė A, Mačionienė E, Ašakienė E. Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5573] [Reference Citation Analysis]
14 Singh P, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder. Front Neurol 2021;12:696387. [PMID: 34803867 DOI: 10.3389/fneur.2021.696387] [Reference Citation Analysis]
15 Truffot A, Jourdil JF, Seitz-Polski B, Malvezzi P, Brglez V, Stanke-Labesque F, Gautier-Veyret E. Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits. Clin Biochem 2021;87:60-6. [PMID: 33096054 DOI: 10.1016/j.clinbiochem.2020.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Noris M. The case of complement inhibitors. Adv Biol Regul 2021;81:100822. [PMID: 34454870 DOI: 10.1016/j.jbior.2021.100822] [Reference Citation Analysis]
17 Sethi A, Moses R. Atypical Hemolytic Uremic Syndrome: Cancer-Induced or Chemotherapy-Induced? Cureus 2021;13:e13260. [PMID: 33717763 DOI: 10.7759/cureus.13260] [Reference Citation Analysis]
18 Saida K, Fukuda T, Mizuno K, Ogura M, Kamei K, Ito S. Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up. Front Pediatr 2019;7:519. [PMID: 31921730 DOI: 10.3389/fped.2019.00519] [Reference Citation Analysis]
19 Rodolico C, Nicocia G, Damato V, Antonini G, Liguori R, Evoli A. Benefit and danger from immunotherapy in myasthenia gravis. Neurol Sci 2021;42:1367-75. [PMID: 33543421 DOI: 10.1007/s10072-021-05077-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Vitiello A, Ferrara F. Commentary of the mRNA vaccines COVID-19. Asian J Pharm Sci 2021;16:531-2. [PMID: 34849160 DOI: 10.1016/j.ajps.2021.05.004] [Reference Citation Analysis]
21 Vitiello A, Ferrara F. Brief review of the mRNA vaccines COVID-19. Inflammopharmacology 2021;29:645-9. [PMID: 33932192 DOI: 10.1007/s10787-021-00811-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Iluta S, Pasca S, Dima D, Mester G, Urian L, Bojan A, Zdrenghea M, Trifa A, Balacescu O, Tomuleasa C. Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease. Eur J Hosp Pharm 2021:ejhpharm-2021-002694. [PMID: 33541912 DOI: 10.1136/ejhpharm-2021-002694] [Reference Citation Analysis]
23 Kulasekararaj AG, Brodsky RA, Nishimura JI, Patriquin CJ, Schrezenmeier H. The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol 2022;13:20406207221091046. [PMID: 35663504 DOI: 10.1177/20406207221091046] [Reference Citation Analysis]
24 Agostinis C, Balduit A, Mangogna A, Zito G, Romano F, Ricci G, Kishore U, Bulla R. Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target. Front Immunol 2020;11:599117. [PMID: 33505394 DOI: 10.3389/fimmu.2020.599117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
25 Jensen EG, Jakobsen TS, Thiel S, Askou AL, Corydon TJ. Associations between the Complement System and Choroidal Neovascularization in Wet Age-Related Macular Degeneration. Int J Mol Sci 2020;21:E9752. [PMID: 33371261 DOI: 10.3390/ijms21249752] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Smith VM, Nguyen H, Rumsey JW, Long CJ, Shuler ML, Hickman JJ. A Functional Human-on-a-Chip Autoimmune Disease Model of Myasthenia Gravis for Development of Therapeutics. Front Cell Dev Biol 2021;9:745897. [PMID: 34881241 DOI: 10.3389/fcell.2021.745897] [Reference Citation Analysis]
27 Tromp AT, Zhao Y, Jongerius I, Heezius ECJM, Abrial P, Ruyken M, van Strijp JAG, de Haas CJC, Spaan AN, van Kessel KPM, Henry T, Haas PA. Pre-existing antibody-mediated adverse effects prevent the clinical development of a bacterial anti-inflammatory protein. Dis Model Mech 2020;13:dmm045534. [PMID: 32471891 DOI: 10.1242/dmm.045534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Benoit SW, Fukuda T, Vandenheuvel K, Witte D, Fuller C, Willis J, Dixon BP, Drake KA. Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing. Front Pediatr 2022;10:841051. [DOI: 10.3389/fped.2022.841051] [Reference Citation Analysis]
29 Lau-Braunhut SA, Stone H, Collins G, Berentsen S, Braun BS, Zinter MS. Paroxysmal cold hemoglobinuria successfully treated with complement inhibition. Blood Adv 2019;3:3575-8. [PMID: 31738828 DOI: 10.1182/bloodadvances.2019000897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Awidi M, Jain M, Baur R. Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim. Eur J Case Rep Intern Med 2021;8:002294. [PMID: 33768076 DOI: 10.12890/2021_002294] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Giglhuber K, Berthele A. Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Immunotherapy 2020;12:1053-66. [PMID: 32772617 DOI: 10.2217/imt-2020-0163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 van den Broek B, van der Flier M, van de Kar NCAJ, Wetzels JFM, de Jonge MI, de Groot R, Wijnsma KL, Langereis JD. Eculizumab impairs killing of Neisseria meningitidis serogroup B in atypical hemolytic uremic syndrome patients vaccinated with MenB-4C. Kidney Int 2022;101:1293-5. [PMID: 35597592 DOI: 10.1016/j.kint.2022.03.010] [Reference Citation Analysis]
33 McCombe JA, Pittock SJ. Anti-complement Agents for Autoimmune Neurological Disease. Neurotherapeutics 2022. [PMID: 35553024 DOI: 10.1007/s13311-022-01223-w] [Reference Citation Analysis]
34 Goldstein J, Nuñez-Goluboay K, Pinto A. Therapeutic Strategies to Protect the Central Nervous System against Shiga Toxin from Enterohemorrhagic Escherichia coli. Curr Neuropharmacol 2021;19:24-44. [PMID: 32077828 DOI: 10.2174/1570159X18666200220143001] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
36 Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P. Complement Inhibition for the Treatment of Myasthenia Gravis. Immunotargets Ther 2020;9:317-31. [PMID: 33365280 DOI: 10.2147/ITT.S261414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. Front Neurol 2020;11:538. [PMID: 32714266 DOI: 10.3389/fneur.2020.00538] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Passot C, Sberro-Soussan R, Bertrand D, Caillard S, Schvartz B, Domenger C, Contin-Bordes C, Paintaud G, Halimi JM, Ternant D, Gatault P. Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. Br J Clin Pharmacol 2021;87:2236-46. [PMID: 33118186 DOI: 10.1111/bcp.14627] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 2020;98:314-322. [PMID: 32461141 DOI: 10.1016/j.kint.2020.05.013] [Cited by in Crossref: 116] [Cited by in F6Publishing: 110] [Article Influence: 58.0] [Reference Citation Analysis]
40 Badri P, Jiang X, Borodovsky A, Najafian N, Kim J, Clausen VA, Goel V, Habtemariam B, Robbie GJ. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet 2021;60:365-78. [PMID: 33047216 DOI: 10.1007/s40262-020-00940-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Riegger J, Brenner RE. Pathomechanisms of Posttraumatic Osteoarthritis: Chondrocyte Behavior and Fate in a Precarious Environment. Int J Mol Sci 2020;21:E1560. [PMID: 32106481 DOI: 10.3390/ijms21051560] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
42 Bouwmeester RN, Ter Avest M, Wijnsma KL, Duineveld C, Ter Heine R, Volokhina EB, Van Den Heuvel LPWJ, Wetzels JFM, van de Kar NCAJ. Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient. Front Immunol 2020;11:612706. [PMID: 33519821 DOI: 10.3389/fimmu.2020.612706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Vitiello A, La Porta R, D'Aiuto V, Ferrara F. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol 2021;82:264-9. [PMID: 33632561 DOI: 10.1016/j.humimm.2021.01.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
44 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Tomazos I, Sierra JR, Johnston KM, Cheung A, Brodsky RA, Weitz IC. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab. Hematology 2020;25:327-34. [PMID: 32856539 DOI: 10.1080/16078454.2020.1807226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Daly RC, Rosenbaum AN, Dearani JA, Clavell AL, Pereira NL, Boilson BA, Frantz RP, Behfar A, Dunlay SM, Rodeheffer RJ, Schirger JA, Taner T, Gandhi MJ, Heimbach JK, Rosen CB, Edwards BS, Kushwaha SS. Heart-After-Liver Transplantation Attenuates Rejection of Cardiac Allografts in Sensitized Patients. J Am Coll Cardiol 2021;77:1331-40. [PMID: 33706876 DOI: 10.1016/j.jacc.2021.01.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Tang Y, Cao Y. Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. Pharmaceutics 2021;13:422. [PMID: 33800976 DOI: 10.3390/pharmaceutics13030422] [Reference Citation Analysis]
48 Nasonov EL, Reshetnyak TM, Alekberova ZS. [Thrombotic microangiopathy in rheumatology: a link between thrombosis and autoimmunity]. Ter Arkh 2020;92:4-14. [PMID: 32598770 DOI: 10.26442/00403660.2020.05.000697] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
49 Mantegazza R, Cavalcante P. Eculizumab for the treatment of myasthenia gravis. Expert Opin Biol Ther 2020;20:991-8. [PMID: 32602752 DOI: 10.1080/14712598.2020.1786530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 2021;20:60-7. [PMID: 33186537 DOI: 10.1016/S1474-4422(20)30392-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
51 Kulagin AD, Ptushkin VV, Lukina EA, Davydkin IL, Korobkin AV, Shamrai VS, Konstantinova TS, Kaporskaya TS, Mitina TA, Ksenzova TI, Zuev EV, Markova OA, Gapchenko EV, Kudlay DA. Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab. Ann Hematol 2021. [PMID: 34398258 DOI: 10.1007/s00277-021-04624-7] [Reference Citation Analysis]